Effect of Rosuvastatin on the Clinical Features of Preeclampsia

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The primary outcome will be the effect of rosuvastatin on the resolution of biochemical features associated with severe PE (↑CRP and IL6).

.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Age: 20-35 years.

• Singleton nonanomalous pregnancy (confirmed with an ultrasound examination).

• Normal lipid profile and normal liver transaminases.

• WBCs (4-11*103/mm3).

• CRP < 3 mg/L.

Exclusion Criteria:

• Parturient's refusal.

• Women with history of cardiac, respiratory, renal, neurologic or endocrine diseases.

• Contraindications for statin therapy (eg, hypersensitivity to rosuvastatin, recent or active liver disease).

• Concomitant therapy with fibrates, niacin, cyclosporine, clarithromycin, or erythromycin.

• Inability to tolerate oral medications secondary to severe nausea and vomiting of pregnancy.

• Multifetal gestation or fetal demise.

• Fetal abnormalities.

• Emergency surgeries.